Acadia Pharmaceuticals (ACAD) Net Equity Issued and Repurchased (2010 - 2026)

Acadia Pharmaceuticals' Net Equity Issued and Repurchased history runs 17 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased rose 130.2% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $52.3 million (up 584.24% YoY), while the FY2025 annual figure was $49.9 million, up 628.75% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $4.2 million, down from $22.7 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $22.7 million in Q4 2025, with the low at $268000.0 in Q3 2024.
• The 5-year median for Net Equity Issued and Repurchased is $3.6 million (2024), against an average of $5.5 million.
• The sharpest annual moves came in 2023 and 2024: Net Equity Issued and Repurchased jumped 4342.86% in 2023, then sank 97.9% in 2024.
• Acadia Pharmaceuticals' Net Equity Issued and Repurchased stood at $1.6 million in 2022, then jumped by 236.68% to $5.4 million in 2023, then plunged by 63.77% to $2.0 million in 2024, then surged by 1051.14% to $22.7 million in 2025, then plunged by 81.33% to $4.2 million in 2026.
• Business Quant data shows ACAD's Net Equity Issued and Repurchased at $4.2 million in Q1 2026, $22.7 million in Q4 2025, and $9.4 million in Q3 2025.